Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Wellcome Trust
Headquarters: London, United Kingdom
Website: http://www.wellcome.ac.uk
Year Founded: 1936
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Dec 23, 2023
Deals
Persistence, creative combinations behind Karuna’s $14B exit
BMS acquires Karuna, brightening the spotlight on schizophrenia, muscarinic receptors and neurology
BioCentury | May 26, 2023
Politics, Policy & Law
U.K. £650M financing package includes major boost for UK Biobank
Financing policies include streamlined trial approvals, investment vehicles for pensions
BioCentury | Aug 8, 2022
Product Development
Karuna’s Phase III schizophrenia success primes company for takeout
Results validate CEO Steven Paul’s ‘simple but elegant’ approach to improving xanomeline’s tolerability in schizophrenia patients
BioCentury | Jul 5, 2022
Product Development
Fresh funding helps CARB-X home in on first-in-class strategies
Partnership kick-starts AMR innovation, but progress on U.S. pull incentives awaits Congressional action
BioCentury | Jun 6, 2022
Deals
Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger
Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
BioCentury | Apr 7, 2022
Deals
VCs realize exit as Pfizer adds RSV therapy via ReViral takeout
Early investors including Andera, OrbiMed gain liquidity in deal worth up to $525M, giving Pfizer an antiviral for RSV
BioCentury | Mar 26, 2022
Product Development
Replenishing CEPI
The Coalition for Epidemic Preparedness Innovations is gearing up to take the fight beyond COVID-19
BioCentury | Mar 10, 2022
Product Development
Global mRNA, biologics manufacturing gaining momentum
WHO backing mRNA vaccine capacity, Korea providing a global biomanufacturing training center
BioCentury | Mar 2, 2022
Management Tracks
Former CDC Director Gerberding to lead FNIH
Merck executive brings deep experience with infectious disease, patient engagement and public health emergencies to the non-profit
BioCentury | Jan 12, 2022
Management Tracks
Alector’s Robert Paul becomes CEO at Nine Square
Plus Smeal joins Cardiff as CSO and updates from GHIT, Aclaris, Iovance, Pyramid, SomaLogic and more
Items per page:
1 - 10 of 517